SK Biopharmaceuticals Co., Ltd. (KRX:326030)

South Korea · Delayed Price · Currency is KRW

76,900

+2,000 (2.67%)

Oct 23, 2026, 3:30 PM KST

Revenue by Segment

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016
New Drug Development Business	706.74B	547.60B	354.89B	246.18B	418.64B
Total	706.74B	547.60B	354.89B	246.18B	418.64B

Revenue by Geography

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016
United States of America	642.66B	438.66B	288.79B	388.21B	267.22B
Switzerland	33.25B	42.33B	12.77B	-	-
Korea	100.00M	6.01B	-	214.94B	455.25B
Cayman Islands	4.17B	35.84B	14.15B	-	-
Consolidation	-	-	-	-356.97B	-303.83B
Japan	12.91B	10.24B	12.77B	-	-
Malta	11.38B	12.26B	12.70B	-	-
Other Countries	2.27B	2.25B	13.70B	-	-
Total	706.74B	547.60B	354.89B	246.18B	418.64B